Pathogenesis of HIV-HCV coinfection

Current Infectious Disease Reports

Volumn 9, Issue 4, 2007, Pages 331-337

  Kim, Arthur Y ^b   Lauer, Georg M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INTERFERON; VIRUS RNA;

ANTIVIRAL ACTIVITY; CELLULAR IMMUNITY; DISEASE ASSOCIATION; DISEASE COURSE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOTHERAPY; INNATE IMMUNITY; LIVER FIBROSIS; NONHUMAN; PATHOGENESIS; PREVALENCE; QUANTITATIVE ANALYSIS; REVIEW; RISK FACTOR; SUPERINFECTION; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

EID: 34547405242     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-007-0051-y     Document Type: Review

References (61)

1. Sulkowski MS, Thomas DL: Hepatitis C in the HIV-infected person. Ann Intern Med 2003, 138:197-207.
2. Alter MJ: Epidemiology of hepatitis C. Hepatology 1997, 26:62S-65S.
3. Thomas DL, Astemborski J, Rai RM, et al.: The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000, 284:450-456.
4. Thomas DL, Shih JW, Alter HJ, et al.: Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996, 174:690-695.
5. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ: Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 1994, 84:1020-1023.
6. Benhamou Y, Di Martino V, Bochet M, et al.: Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001, 34:283-287.
7. Bowen DG, Walker CM: Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005, 436:946-952.
8. Gale M Jr, Foy EM: Evasion of intracellular host defence by hepatitis C virus. Nature 2005, 436:939-945.
9. Bigger CB, Guerra B, Brasky KM, et al.: Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol 2004, 78:13779-13792.
10. Khakoo SI, Thio CL, Martin MP, et al.: HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004, 305:872-874.
11. Crotta S, Stilla A, Wack A, et al.: Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 2002, 195:35-41.
12. Cox AL, Mosbruger T, Lauer GM, et al.: Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology 2005, 42:104-112.
13. Timm J, Lauer GM, Kavanagh DG, et al.: CD8 epitope escape and reversion in acute HCV infection. J Exp Med 2004, 200:1593-1604.
14. Tester I, Smyk-Pearson S, Wang P, et al.: Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. J Exp Med 2005, 201:1725-1731.
15. Cox AL, Mosbruger T, Mao Q, et al.: Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med 2005, 201:1741-1752.
16. Wedemeyer H, He XS, Nascimbeni M, et al.: Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 2002, 169:3447-3458.
17. Gilleece YC, Browne RE, Asboe D, et al.: Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr 2005, 40:41-46.
18. Danta M, Semmo N, Northfield J, et al.: HCV-specific T-cell responses of acutely HCV infected individuals with and without HIV [abstract 561]. Presented at The Liver Meeting: 56th Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco; November 11-15, 2005.
19. Puro V, Petrosillo N, Ippolito G: Risk of hepatitis C seroconversion after occupational exposures in health care workers. Italian Study Group on Occupational Risk of HIV and Other Bloodborne Infections. Am J Infect Control 1995, 23:273-277.
20. Cardo DM, Culver DH, Ciesielski CA, et al.: A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997, 337:1485-1490.
21. Kim AY, Schulze Zur Wiesch J, Kuntzen T, et al.: Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection. PLoS Med 2006, 3:e492.
22. Kim AY, Lauer GM, Ouchi K, et al.: The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1. Blood 2005, 105:1170-1178.
23. Dutoit V, Ciuffreda D, Comte D, et al.: Differences in HCV-specific T cell responses between chronic HCV infection and HIV/HCV co-infection. Eur J Immunol 2005, 35:3493-3504.
24. Lee WM, Polson JE, Carney DS, et al.: Reemergence of hepatitis C virus after 8.5 years in a patient with hypogammaglobulinemia: evidence for an occult viral reservoir. J Infect Dis 2005, 192:1088-1092.
25. Laskus T, Radkowski M, Piasek A, et al.: Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes. J Infect Dis 2000, 181:442-448.
26. Li Q, Duan L, Estes JD, et al.: Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 2005, 434:1148-1152.
27. Mattapallil JJ, Douek DC, Hill B, et al.: Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 2005, 434:1093-1097.
28. Guadalupe M, Sankaran S, George MD, et al.: Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J Virol 2006, 80:8236-8247.
29. Harcourt G, Gomperts E, Donfield S, Klenerman P: Diminished frequency of hepatitis C virus specific interferon gamma secreting CD4+ T cells in human immunodeficiency virus/hepatitis C virus coinfected patients. Gut 2006, 55:1484-1487.
30. Frese M, Schwarzle V, Barth K, et al.: Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 2002, 35:694-703.
31. Valdez H, Carlson NL, Post AB, et al.: HIV long-term nonprogressors maintain brisk CD8 T cell responses to other viral antigens. AIDS 2002, 16:1113-1118.
32. Alatrakchi N, Martino VD, Thibault V, Autran B: Strong CD4 Th1 responses to HIV and hepatitis C virus in HIV-infected long-term non-progressors co-infected with hepatitis C virus. AIDS 2002, 16:713-717.
33. Anthony DD, Yonkers NL, Post AB, et al.: Selective impairments in dendritic cell-associated function distinguish hepatitis C virus and HIV infection. J Immunol 2004, 172:4907-4916.
34. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al.: Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, 351:438-450.
35. Pawlotsky JM: Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol 2004, 12:96-102.
36. Graham CS, Baden LR, Yu E, et al.: Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001, 33:562-569.
37. Prieto M, Berenguer M, Rayon JM, et al.: High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999, 29:250-256.
38. Leroy V, Vigan I, Mosnier JF, et al.: Phenotypic and functional characterization of intrahepatic T lymphocytes during chronic hepatitis C. Hepatology 2003, 38:829-841.
39. Spangenberg HC, Viazov S, Kersting N, et al.: Intrahepatic CD8+ T-cell failure during chronic hepatitis C virus infection. Hepatology 2005, 42:828-837.
40. Wynn TA: Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004, 4:583-594.
41. Accapezzato D, Francavilla V, Paroli M, et al.: Hepatic expansion of a virus-specific regulatory CD8+ T cell population in chronic hepatitis C virus infection. J Clin Invest 2004, 113:963-972.
42. Graziosi C, Pantaleo G, Gantt KR, et al.: Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals. Science 1994, 265:248-252.
43. Elrefaei M, Barugahare B, Ssali F, et al.: HIV-specific IL-10-positive CD8+ T cells are increased in advanced disease and are associated with decreased HIV-specific cytolysis. J Immunol 2006, 176:1274-1280.
44. Gremion C, Grabscheid B, Wolk B, et al.: Cytotoxic T lymphocytes derived from patients with chronic hepatitis C virus infection kill bystander cells via Fas-FasL interaction. J Virol 2004, 78:2152-2157.
45. Graham CS, Curry M, He Q, et al.: Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV. Hepatology 2004, 40:125-132.
46. Alatrakchi N, Graham CS, He Q, et al.: CD8+ cell responses to hepatitis C virus (HCV) in the liver of persons with HCV-HIV coinfection versus HCV monoinfection. J Infect Dis 2005, 191:702-709.
47. Canchis PW, Yee HT, Fiel MI, et al.: Intrahepatic CD4+ cell depletion in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr 2004, 37:1125-1131.
48. Yokozaki S, Takamatsu J, Nakano I, et al.: Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: influence of antiretroviral therapy. Blood 2000, 96:4293-4299.
49. Torti C, Barnes E, Quiros-Roldan E, et al.: Suppression of hepatitis C virus replication is maintained long term following HAART therapy, in an individual with HCV/HIV co-infection. Antivir Ther 2004, 9:139-142.
50. Cooper CL, Cameron DW: Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA levels in human immunodeficiency virus and HCV coinfection. Clin Infect Dis 2002, 35:873-879.
51. Babik JM, Holodniy M: Impact of highly active antiretroviral therapy and immunologic status on hepatitis C virus quasispecies diversity in human immunodeficiency virus/hepatitis C virus-coinfected patients. J Virol 2003, 77:1940-1950.
52. Blackard JT, Yang Y, Bordoni P, et al.: Hepatitis C virus (HCV) diversity in HIV-HCV-coinfected subjects initiating highly active antiretroviral therapy. J Infect Dis 2004, 189:1472-1481.
53. Qurishi N, Kreuzberg C, Luchters G, et al.: Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003, 362:1708-1713.
54. Brau N, Salvatore M, Rios-Bedoya CF, et al.: Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006, 44:47-55.
55. Xiang J, Wunschmann S, Diekema DJ, et al.: Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med 2001, 345:707-714.
56. Deayton JR, Prof Sabin CA, Johnson MA, et al.: Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet 2004, 363:2116-2121.
57. Yao ZQ, Waggoner SN, Cruise MW, et al.: SOCS1 and SOCS3 are targeted by hepatitis C virus core/gC1qR ligation to inhibit T-cell function. J Virol 2005, 79:15417-15429.
58. Greub G, Ledergerber B, Battegay M, et al.: Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000, 356:1800-1805.
59. McGovern BH, Golan Y, Lopez M, et al.: The impact of cirrhosis on CD4+ T-cell counts in HIV-seronegative patients. Clin Infect Dis 2007, 44:431-437.
60. De Francesco R, Migliaccio G: Challenges and successes in developing new therapies for hepatitis C. Nature 2005, 436:953-960.
61. Winnock M, Salmon-Ceron D, Dabis F, Chene G: Interaction between HIV-1 and HCV infections: towards a new entity? J Antimicrob Chemother 2004, 53:936-946.